These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 12804699)
1. Antisense therapeutics: from theory to clinical practice. Pirollo KF; Rait A; Sleer LS; Chang EH Pharmacol Ther; 2003 Jul; 99(1):55-77. PubMed ID: 12804699 [TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotides: the state of the art. Aboul-Fadl T Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780 [TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotides as therapeutics for malignant diseases. Ho PT; Parkinson DR Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689 [TBL] [Abstract][Full Text] [Related]
5. Towards genomic drug therapy with antisense oligonucleotides. Lönnberg H; Vuorio E Ann Med; 1996 Dec; 28(6):511-22. PubMed ID: 9017110 [TBL] [Abstract][Full Text] [Related]
6. Antisense-based cancer therapeutics: are we there yet? Rayburn ER; Wang H; Zhang R Expert Opin Emerg Drugs; 2006 May; 11(2):337-52. PubMed ID: 16634705 [TBL] [Abstract][Full Text] [Related]
7. Antisense anticancer oligonucleotide therapeutics. Wang H; Prasad G; Buolamwini JK; Zhang R Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878 [TBL] [Abstract][Full Text] [Related]
8. Clinical development of antisense oligonucleotides as anti-cancer therapeutics. Chen HX Methods Mol Med; 2003; 75():621-36. PubMed ID: 12407768 [No Abstract] [Full Text] [Related]
9. Antisense therapy: recent advances and relevance to prostate cancer. Benimetskaya L; Stein CA Clin Prostate Cancer; 2002 Jun; 1(1):20-30. PubMed ID: 15046709 [TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides: a new therapeutic approach. Temsamani J; Guinot P Biotechnol Appl Biochem; 1997 Oct; 26(2):65-71. PubMed ID: 9357101 [TBL] [Abstract][Full Text] [Related]
11. Antisense and/or immunostimulatory oligonucleotide therapeutics. Agrawal S; Kandimalla ER Curr Cancer Drug Targets; 2001 Nov; 1(3):197-209. PubMed ID: 12188879 [TBL] [Abstract][Full Text] [Related]
12. Oligonucleotide technologies: synthesis, production, regulations and applications. 29-30th November 2000, Hamburg, Germany. Uhlmann E Expert Opin Biol Ther; 2001 Mar; 1(2):319-28. PubMed ID: 11727539 [TBL] [Abstract][Full Text] [Related]
13. Locked nucleic acid holds promise in the treatment of cancer. Frieden M; Ørum H Curr Pharm Des; 2008; 14(11):1138-42. PubMed ID: 18473860 [TBL] [Abstract][Full Text] [Related]
14. Current status of delivery systems to improve target efficacy of oligonucleotides. Shoji Y; Nakashima H Curr Pharm Des; 2004; 10(7):785-96. PubMed ID: 15032703 [TBL] [Abstract][Full Text] [Related]
15. Nucleic acid modulation of gene expression: approaches for nucleic acid therapeutics against cancer. Nakata Y; Kim TK; Shetzline S; Gewirtz AM Crit Rev Eukaryot Gene Expr; 2005; 15(2):163-82. PubMed ID: 16022634 [TBL] [Abstract][Full Text] [Related]
17. Oligonucleotides as anticancer agents: from the benchside to the clinic and beyond. Coppelli FM; Grandis JR Curr Pharm Des; 2005; 11(22):2825-40. PubMed ID: 16101440 [TBL] [Abstract][Full Text] [Related]